Skip To Main Content
J. Pasquau on Muck Rack

J. Pasquau

As seen in: Journal of Antimicrobial Chemotherapy
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile
Back to J. Pasquau’s profile

Articles by J. Pasquau

Simplification to dual therapy (atazanavir/ritonavir + lamivudine) versus standard triple therapy [atazanavir/ritonavir + two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority,

|
By J. A. Perez-Molina, R. Francis. Rubio, A. Rivero, J. Pasquau
| Journal of Antimicrobial Chemotherapy Verified
Objectives We evaluated whether maintenance therapy with atazanavir/ritonavir plus lamivudine (ATV/r?+?3TC) was non-inferior to ATV/r plus two nucleosides (ATV/r?+?2NUCs) at 96 weeks of follow-up. Methods SALT is a multicentre, open-label, non-inferiority clinical trial in HIV-1-infected virologically suppressed patients.
Open in Who Shared Issue with article?

Simplification to dual therapy (atazanavir/ritonavir + lamivudine) versus standard triple therapy [atazanavir/ritonavir + two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority,

|
By R. Francis. Rubio, A. Rivero, J. A. Perez-Molina, J. Pasquau
| Journal of Antimicrobial Chemotherapy Verified
Objectives We evaluated whether maintenance therapy with atazanavir/ritonavir plus lamivudine (ATV/r?+?3TC) was non-inferior to ATV/r plus two nucleosides (ATV/r?+?2NUCs) at 96 weeks of follow-up. Methods SALT is a multicentre, open-label, non-inferiority clinical trial in HIV-1-infected virologically suppressed patients.
Open in Who Shared Issue with article?
Show More